助手标题  
全文文献 工具书 数字 学术定义 翻译助手 学术趋势 更多
查询帮助
意见反馈
   acute stroke trials 的翻译结果: 查询用时:0.008秒
图标索引 在分类学科中查询
所有学科
更多类别查询

图标索引 历史查询
 

acute stroke trials
相关语句
  急性脑卒中临床试验
     Methods of Outcome Assessment in Chinese Acute Stroke Trials
     我国急性脑卒中临床试验疗效判断方法分析
短句来源
     Objective To learn if appropriate methods and clinically relevant outcomes were used by analyzing methods of outcome assessment in Chinese acute stroke trials.
     目的 了解国内急性脑卒中临床试验疗效判断方法的现状和存在的问题。
短句来源
  相似匹配句对
     Methods of Outcome Assessment in Chinese Acute Stroke Trials
     我国急性脑卒中临床试验疗效判断方法分析
短句来源
     Locus of acute stroke and dyssomnia
     急性脑卒中病灶发生部位与患者的睡眠障碍
短句来源
     for acute hemorrhagic stroke was hypertension.
     对出血性脑卒中发病危险的独立影响因素只有高血压。
短句来源
     Hyperbaric oxygen for acute ischemic stroke: a systematic review of randomized controlled trials
     高压氧治疗急性缺血性脑卒中近期疗效的系统评价
短句来源
     Hyperbaric Oxygen for Acute Ischemic Stroke:a Systematic Review of Randomized Controlled Trials
     高压氧治疗急性缺血性脑卒中的疗效随机对照试验的系统评价
短句来源
查询“acute stroke trials”译词为用户自定义的双语例句

    我想查看译文中含有:的双语例句
例句
为了更好的帮助您理解掌握查询词或其译词在地道英语中的实际用法,我们为您准备了出自英文原文的大量英语例句,供您参考。
  acute stroke trials
Use of the Barthel Index and Modified Rankin Scale in acute stroke trials.
      
The first topic was novel approaches to statistical design of acute stroke trials and appropriate outcome measures.
      
Surrogate outcome measures for acute stroke trials may be useful, but remain to be fully validated, in relationship to accepted clinical outcomes.
      
Center selection criteria included extensive prior experience in acute stroke trials and NIHSS certification.
      


The advances of antithrombotic agents in cerebral ischemia were reviewed. There are three kinds of drugs available named antiplatelet agents, anticoagulants and thrombolytics, for treatment of cerebral ischemia. Antiplatelet agents are considered the most beneficial in thrombotic stroke, they can reduce the risk of cerebral ischemia relapse by 25-30%. Of which, aspirin is typically the choice of antiplatelet agent for cerebral ischemia prevention. Ticlopidine is more effective than aspirin in thrombotic stroke...

The advances of antithrombotic agents in cerebral ischemia were reviewed. There are three kinds of drugs available named antiplatelet agents, anticoagulants and thrombolytics, for treatment of cerebral ischemia. Antiplatelet agents are considered the most beneficial in thrombotic stroke, they can reduce the risk of cerebral ischemia relapse by 25-30%. Of which, aspirin is typically the choice of antiplatelet agent for cerebral ischemia prevention. Ticlopidine is more effective than aspirin in thrombotic stroke prevention, but its severe adverse drug reactions restrict its use.Anticoagulants are highly effective for prevention of cerebral ischemia caused by cardiac embolism,but their effectiveness in non-cardioembolic stroke is uncertain, and blood monitoring should be warranted during their uses. Thrombolytic therapy as early as possible after ischemic stroke onset is beneficial to reperfusion and prevention of neuronal damage. In addition, when given within 6 hours of ischemia onset, thrombolytics appear to be relatively safe and effective.However, recent multicentre acute stroke trials found excess of early deaths and intracerebral haetniorrhages, although improvement of clinical symptom come over long term. The benefit of thrombolys is in therapy should be evalu-ated extensively. Several newly developed antithrombotic agents, such as direct antithrombins, specific antiplatelet agents and new anticoagulation inhibitors, are being evaluated.

本文对防治缺血性脑血管病的抗栓药物研究进展进行了综述,主要有抗血小板药。抗凝药、溶栓药。阿司匹林是最常用于防治缺血性脑血管病的药物,噻氯匹啶虽然效果好,但由于不良反应多且严重,从而限制了其临床应用,仅作为对阿司匹林不能耐受的二线药,而抗血小板药仅能降低25-30%的危险性;抗凝药对防治因心源性栓塞所致的缺血性脑血管病有效,但是否可用于防治非心源性栓塞所致的缺血性脑血管病尚不清楚,且需进行血液学监护;尽早应用溶栓药有益于促进脑血管的再灌,治疗缺血性脑血管病,在发作后6h内使用溶栓药的效果较好且较安全,然而最近一些多中心临床试验发现溶栓治疗虽可改善临床症状和减少致残,但有增加患者脑溢血及死亡的危险。因此,如何保证溶栓治疗的安全性值得深入探讨。一些新型抗栓药物如直接凝血酶抑制药。特异性抗血小板药及新型抗凝药等正在开发研究之中,临床前研究结果表明这些药物在防治缺血性脑血管疾病中具有一定的应用前景,但仅限于临床前试验,其防治缺血性脑血管病的有效性和安全性尚需深入研究。

Objective:To obtain a reliable assessment of the separate effects on mortality and on disability in survivors of AcuteStroke.Methods:The Chinese Acute Stroke Trial(CAST) was a large randomized, placeboontrolled trial of the effects in hospital of aspirin treatment 160 mg per day started with in 48 h of the onset of suspected acute ischaemic stroke and continuedin hospital for up to 4 weeks.Results: There was a significant 14.0 % (s=7.0) proportional reduction in mortality[343(3. 3 % )...

Objective:To obtain a reliable assessment of the separate effects on mortality and on disability in survivors of AcuteStroke.Methods:The Chinese Acute Stroke Trial(CAST) was a large randomized, placeboontrolled trial of the effects in hospital of aspirin treatment 160 mg per day started with in 48 h of the onset of suspected acute ischaemic stroke and continuedin hospital for up to 4 weeks.Results: There was a significant 14.0 % (s=7.0) proportional reduction in mortality[343(3. 3 % ) deaths among aspiringroup vs 398 (3. 9 % ) deaths among placebo group, p=0. 04]. There were significantly fewer recurrent ischaemic strokes inthe aspirin group than in the placebo group[167 (1. 6 % )vs 215 (2. 1% ),p=0. 01],slightly more haemorrhagic strokes[115(1. 1 %) vs 93(0. 9% ),P>0. 1].Conclusion:The present study shows that aspirin started early in hospital produces a significant reduction in mortalityand recurrent stroke during the treatment period,with perhaps slightly less likelihood of functional impairment among thosedischarged alive.

目的:探讨急性缺血性脑卒中早期抗血小板治疗,对降低病人病死率、改善机体残疾率的临床疗效。本试验简称CAST临床试验。方法:采取多中心、随机、双盲治疗。对发病48小时内的急性缺血性脑卒中,经头颅计算机断层摄影术(CT)或临床检查基本排除出血性脑卒中即可入选。每日口服阿司匹林160mg或安慰剂4周。结果:自1993年11月至1997年4月全国413家医院共入选21106例病人。治疗期间阿司匹林组死亡343例,较对照组(死亡398例)下降14.0%(P=0.04)。再发缺血性脑卒中阿司匹林组显著低于对照组(1.6%比2.1%,P=0.01)。出血性脑卒中的发生,阿司匹林组较对照组略有增加,但差别不显著(1.1%比0.9%,P>0.1)。结论:本项研究显示,对急性缺血性脑卒中病人进行早期抗血小板治疗,可显著降低住院期间死亡率及再发脑卒中发生率,并在一定程度上促进病人的功能康复。

1.Department of Hypertension,Fu Wai Hospital,Beijing100037;2.Department of Physiology,Institute of Basic Medical Sciences,Beijing100005;3.Department of Pharmacology,Institute of Materia Medica,Beijing100050;4.Department of Epidemiology,Fu Wai Hospital,Beijing100037; Since1959the investigations on prevalence of hypertension and studies on the prevention and treatment of this disease have been carried out.The vascular mechanism of hypertension and the depressor effect of Chinese traditional herbs were...

1.Department of Hypertension,Fu Wai Hospital,Beijing100037;2.Department of Physiology,Institute of Basic Medical Sciences,Beijing100005;3.Department of Pharmacology,Institute of Materia Medica,Beijing100050;4.Department of Epidemiology,Fu Wai Hospital,Beijing100037; Since1959the investigations on prevalence of hypertension and studies on the prevention and treatment of this disease have been carried out.The vascular mechanism of hypertension and the depressor effect of Chinese traditional herbs were also studied in Chinese Academy of Medical Sciences.The results revealed that:(1)The prevalence of hypertension in Chinese adults increased from7.73%in1979to11.26%in1991,both much higher than that in1959(5.11%).The rate of awareness,treatment and control was only26.3%,12.1%,and2.8%respectively.The risk factors of hypertension included overweight and alcohol drinking.High sodium,low potassium,low calcium,and low animal protein diet were also very important risk for elevation of blood pressure.Hypertension was the most important causal risk factor of coronary heart disease and stroke.(2)Hypertension diagnosis and staging criteria were established in1959.Secondary hypertension was found to constitute1.1%among community hypertensive patients.The new concept of aortitis was formed and found to be the most common cause of renal vascular hypertension.Patient education together with low dose compounds of antihypertensive drugs was implicated widely.Randomized clinical trials Syst-China,Post-stroke Antihypertensive Treatment Study,Chinese Acute Stroke Trial,and Chinese Cardiac Study1demonstrated benefits of treatment for hypertensive,stroke or acute myocardial infarction affordable by Chinese population at large.(3)A series of functional changes and abnormalities with evident hereditary characteristics were found in the processes of cellular Ca 2+ transportation,utilization,metabolism and their modulation of the vascular smooth muscle in SHR,and SHRsp,which seem to be the principal cause of the increase in peripheral vascular resistance in hyp ertension.(4)Alkaloid of Rauwolfia verticilata and Ligustrazine had marked depressor effect.Flavones of Radix Pueraricae could reduce the cardiac and cerebral ischemic damage and symptoms in hypertensive patients.

为探讨我国高血压的发病情况,研究高血压的防治和发病机制,中国医学科学院阜外医院高血压研究室与流行病学研究室,基础医学研究所生理学系及药物研究所药理学研究室自1959年始陆续开展了全国高血压流行病学调查和人群防治试点、高血压治疗研究、高血压发病机制研究和中药降压作用研究。研究结果表明:(1)我国高血压的患病率逐年增高,自1959年的5.11%,上升至1979年的7.73%和1991年的11.26%。但患者的知晓率仅26.3%,治疗率仅12.1%,控制率仅2.8%。体重超重和经常饮酒是我国高血压的危险因素,高钠、低钾、低钙及低蛋白饮食是血压升高的因素。我国人群中血压升高是冠心病和脑卒中发病的最重要危险因素。(2)建立了我国高血压诊断和分期标准。发现在我国高血压患者中继发性高血压仅占1.1%。率先提出了大动脉炎的概念并发现大动脉炎是肾性高血压的主要原因。对患者进行身心教育调动其主观能动性,加以低剂量的复方降压制剂有效地促进了群防群治工作的开展。大样本多中心随机对照临床实验证实,对高血压性脑卒中和心肌梗死的治疗可明显降低其再发和死亡危险。(3)对实验性高血压大鼠阻力动脉平滑肌收缩机制研究证明,血管平滑肌细胞Ca2+转...

为探讨我国高血压的发病情况,研究高血压的防治和发病机制,中国医学科学院阜外医院高血压研究室与流行病学研究室,基础医学研究所生理学系及药物研究所药理学研究室自1959年始陆续开展了全国高血压流行病学调查和人群防治试点、高血压治疗研究、高血压发病机制研究和中药降压作用研究。研究结果表明:(1)我国高血压的患病率逐年增高,自1959年的5.11%,上升至1979年的7.73%和1991年的11.26%。但患者的知晓率仅26.3%,治疗率仅12.1%,控制率仅2.8%。体重超重和经常饮酒是我国高血压的危险因素,高钠、低钾、低钙及低蛋白饮食是血压升高的因素。我国人群中血压升高是冠心病和脑卒中发病的最重要危险因素。(2)建立了我国高血压诊断和分期标准。发现在我国高血压患者中继发性高血压仅占1.1%。率先提出了大动脉炎的概念并发现大动脉炎是肾性高血压的主要原因。对患者进行身心教育调动其主观能动性,加以低剂量的复方降压制剂有效地促进了群防群治工作的开展。大样本多中心随机对照临床实验证实,对高血压性脑卒中和心肌梗死的治疗可明显降低其再发和死亡危险。(3)对实验性高血压大鼠阻力动脉平滑肌收缩机制研究证明,血管平滑肌细胞Ca2+转运、利用、代谢及其调控因素均发生一系列变化,并具有遗传因素,这是血液循环外周

 
<< 更多相关文摘    
图标索引 相关查询

 


 
CNKI小工具
在英文学术搜索中查有关acute stroke trials的内容
在知识搜索中查有关acute stroke trials的内容
在数字搜索中查有关acute stroke trials的内容
在概念知识元中查有关acute stroke trials的内容
在学术趋势中查有关acute stroke trials的内容
 
 

CNKI主页设CNKI翻译助手为主页 | 收藏CNKI翻译助手 | 广告服务 | 英文学术搜索
版权图标  2008 CNKI-中国知网
京ICP证040431号 互联网出版许可证 新出网证(京)字008号
北京市公安局海淀分局 备案号:110 1081725
版权图标 2008中国知网(cnki) 中国学术期刊(光盘版)电子杂志社